Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerability of S241656 as monotherapy and in combination with other anti-cancer therapies in participants with selected advanced malignancies. The study population for the Dose Escalation part of the study comprises adults with recurrent advanced/metastatic non-small cell lung cancer (NSCLC), Gastrointestinal (GI) cancers, and other solid tumors harboring KRAS, HRAS, NRAS, BRAF, and/or CRAF (Rapidly Accelerated Fibrosarcoma (RAF1)) mutations or al

Trial Details

NCT ID

NCT05786924

Phase

PHASE1 / PHASE2

Sponsor

Institut de Recherches Internationales Servier

Status

RECRUITING

Cancer Type

Lung Cancer

Locations (sample)

Gilbert, Arizona, United States|33.35283,-111.78903
Los Angeles, California, United States|34.05223,-118.24368
Los Angeles, California, United States|34.05223,-118.24368
San Francisco, California, United States|37.77493,-122.41942
Aurora, Colorado, United States|39.72943,-104.83192

Key Eligibility Criteria

Life expectancy of ≥ 12 weeks in the opinion of the investigator.
Histologically or cytologically confirmed recurrent locally advanced (unresectable) or metastatic solid tumors with documented RAS or RAF mutations…
Adequate bone marrow and organ function.
Recovered from toxicity to prior anti-cancer therapy.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →